Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Secondary prevention following coronary artery bypass grafting has improved but remains sub-optimal: the need for targeted follow-up

Lookup NU author(s): Dr Andrew OwensORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

A focused review of secondary preventive medication following revascularisation provides an opportunity to ensure optimal use of these agents. A retrospective analysis of our in-house cardiothoracic surgical database was performed to identify patients undergoing non-emergency, elective surgical revascularisation discharged on four secondary preventive medications: aspirin; beta-blockers; ACE-inhibitors and statins. Of 2749 patients studied, 2302 underwent isolated coronary artery bypass grafting (CABG), mean age 65.5 years (S.D. 9.15). Overall, 2536 (92%) patients were prescribed aspirin. Beta-blockers were prescribed in 2171 (79%) patients overall, in 1096/1360 (81%) of patients with a history of myocardial infarction and in 465/619 (75%) of patients with left ventricular systolic dysfunction (LVSD). Overall, 1518 (55%) patients were prescribed an ACE-inhibitor and 179 (6.5%) an angiotensin receptor blocker (ARB); one of these agents was prescribed in 446/619 (72%) patients with LVSD and 915/1360 (67%) patients with a history of previous myocardial infarction. Overall, 2518 (92%) patients were prescribed a statin. Secondary preventive therapies are prescribed more commonly on discharge after CABG than in previous studies, but there is a continuing under-utilisation of ACE-inhibitors. To maximise the potential benefits of these agents, further study is required to understand why they are not prescribed.

Publication metadata

Author(s): Turley AJ, Roberts AP, Morley R, Thornley AR, Owens WA, deBelder MA

Publication type: Article

Publication status: Published

Journal: Interactive CardioVascular and Thoracic Surgery

Year: 2008

Volume: 7

Issue: 2

Pages: 231-234

ISSN (print): 1569-9293

ISSN (electronic): 1569-9285

Publisher: European Association for Cardio-Thoracic Surgery

URL: http://dx.doi.org/10.1510/icvts.2007.168948

DOI: 10.1510/icvts.2007.168948

PubMed id: 18234766

Altmetrics

Altmetrics provided by Altmetric

Share